For your adult patients with relapsed or refractory multiple myeloma

UNPRECEDENTED mPFS WITH SARCLISA + Kd

LONGEST EVER REPORTED

in a phase 3 trial that included lenalidomide-refractory patients1-6*

*Based on a review of published phase 3 trials that included lenalidomide-refractory patients with RRMM. Interpret with caution, as various factors, including patient population, differ between trials.

SARCLISA + Kd
IKEMA

Final analysis: mPFS 41.7 months with SARCLISA + Kd (n=179) vs 20.8 months with Kd alone (n=123), HR=0.59 (95% CI: 0.42, 0.83) at a median follow-up of 44 months2

Interim analysis: mPFS NR with SARCLISA + Kd vs 20.27 months with Kd alone, HR=0.548 (95% CI: 0.37, 0.82; P=0.0032) at a median follow-up of 20.7 months1

SARCLISA + Kd
IKEMA

Final analysis: mPFS 41.7 months with SARCLISA + Kd (n=179) vs 20.8 months with Kd alone (n=123), HR=0.59 (95% CI: 0.42, 0.83) at a median follow-up of 44 months2

Interim analysis: mPFS NR with SARCLISA + Kd vs 20.27 months with Kd alone, HR=0.548 (95% CI: 0.37, 0.82; P=0.0032) at a median follow-up of 20.7 months1

Watch an expert review the results for SARCLISA + Kd vs Kd alone

"The median PFS of the IKEMA trial reinforces my confidence in prescribing SARCLISA + Kd in my patients with multiple myeloma at first relapse."2

– Dr Joseph Mikhael, MD

See the final PFS analysis from
the IKEMA trial

Explore SARCLISA + Kd

Know when to consider
SARCLISA

Explore a Patient Case

National Comprehensive Cancer Network® (NCCN®) recommends isatuximab-irfc (sarclisa) in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma as a Category 1 Preferred option in combination with carfilzomib and dexamethasone or with pomalidomide and dexamethasone7:

  • ✓ For early relapses (1-3 prior therapies)
  • ✓ Option for patients refractory to either lenalidomide or bortezomib

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Recommendation for isatuximab-irfc (SARCLISA) in combination with carfilzomib and dexamethasone based on results of interim analysis.

After 2 prior therapies including lenalidomide and a proteasome inhibitor for isatuximab-irfc in combination with pomalidomide and dexamethasone.

Kd=carfilzomib and dexamethasone; mPFS=median progression-free survival; NCCN=National Comprehensive Cancer Network® (NCCN®); NR=not reached; PFS=progression-free survival; RRMM=relapsed or refractory multiple myeloma.

Back to topTop